NEWTOWN, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, NeuroHabilitation Corporation, has partnered with Kessler Institute for Rehabilitation and Kessler Foundation, New Jersey-based leaders in rehabilitation care and research, to implement its fourth Clinical Experience Program (CEP) for its Portable Neuromodulation Stimulator (PoNS ). PoNS is a licensed class II medical device in Canada and an investigational medical device in the U.S. and in the EU. PoNS is currently under review for US market clearance by the Food & Drug Administration (FDA) and EU clearance by the EU Notified Body.
